Abstract
OBJECTIVE: To develop a monoclonal antibody (mAb) directed to FVIII C2 domain and investigate its effect on FVIII activity. METHODS: FVIII C2 protein was expressed in E. coli and purified. A murine antihuman FVIII C2 domain mAb SZ-132 was developed by standard hybridoma technology and characterized. In coagulation assays, different concentrations of SZ-132 were incubated with freshly collected pooled human plasma and the residual activity of FVIII and activated partial thromboplastin time (APTT) were determined. The effects of SZ-132 on rhFVIII binding to purified human vWF, phosphatidylserine (PS) and platelets were assessed by enzyme linked immunosorbent assays (ELISA). RESULTS: SZ-132 could inhibit FVIII procoagulant activity in a dose-dependent manner within the concentrations of 0-25 microg/ml and the FVIII activity was completely inhibited on above 25 microg/ml. It could also prevent rhFVIII from binding to vWF, PS and platelets. CONCLUSIONS: SZ-132 is a neutralizing mAb against FVIII C2 domain and can inhibit FVIII procoagulant activity by preventing FVIII from binding to vWF and PS.
Original language | English |
---|---|
Pages (from-to) | 154-157 |
Number of pages | 4 |
Journal | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi |
Volume | 30 |
Issue number | 3 |
State | Published - Mar 2009 |
ASJC Scopus subject areas
- General Medicine